VIDA Diagnostics Inc. news
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the company’s artificial intelligence (
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has onboarded more than 1,000 sites globally in its VIDA network of imaging sites. This network is connected through the VIDA Intelligence Portal, a cloud native AI-enabled platform that drives efficiencies in clinical trial imaging operations by optimizing site recruitment and onboarding, staff training, image data collection, data quality, data curation, and more.<
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage VIDA’s unique AI-enabled biomarker generation service
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has announced it has secured financing as it scales up to support strong demand for its VIDA Intelligence Portal, an AI-powered solution that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Since launching this latest addition to VIDA`s platform five months ago, demand has driven VID
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has received market authorization in Japan for its VIDA Insights® software, paving the way for lung care teams to begin using the solution at the point of care. Clairvo Technologies, Inc., a wholly owned subsidiary of Marubeni Corporation, secured the certification from Japan’s Pharmaceuticals and Medical Devices Agency.
“I am pleased that VID